Equity · Currency in GBp · Last updated Jun 6, 2026
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, which incorporates various user-led improvements to its small, patented gene amplification platform for ease of use in time critical situations, and to simplify workflow, as well as for professional use in emergency healthcare settings. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for targeting various pathogens in the defense applications; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive COV19-ID Kit, an innovative rapid point-of care molecular test for COVID-19. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
GDR.L's Sharpe Ratio of -0.03 indicates that for each unit of volatility, it generates -0.03 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jun 6, 2026).
Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets.
GDR.L Sharpe Ratio Rank
Average
GDR.L ranks above 40.2% of all investments in our database based on Sharpe Ratio over the past 12 months, showing balanced returns relative to total risk taken. Securities are ranked from 0 (worst) to 100 (best).
What moves the rank
Strong returns with low total volatility → Higher rank
High volatility (both upside and downside) → Lower rank
Consistent returns → Higher rank than volatile returns of same magnitude
Sharp drawdowns increase volatility → Lower rank
What you can do with this information
Returns are proportional to volatility—neither strong nor weak
Evaluate whether the volatility profile aligns with your risk tolerance
Review higher-ranked alternatives in the same category
Monitor rank direction to identify improving or deteriorating trends
GDR.L Sharpe Ratio Market Positioning
The chart shows GDR.L's Sharpe Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.
GDR.L: -0.03
S&P 500 Index: 2.28
Red zone (bottom 25%): -0.40 or lower
Yellow zone (middle 50%): -0.40 to 1.11
Green zone (top 25%): 1.11 or higher
Top 1%: 5.33+
Median: 0.21 — half of all investments score higher
How it compares to other similar stocks
The table compares genedrive plc's Sharpe Ratio with other stocks in the Diagnostics & Research industry across multiple time periods, showing how GDR.L's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 6, 2026.
The chart shows GDR.L's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.
Identify market cycles by observing when GDR.L consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.
Loading charts...
Sharpe Ratio Calculator
How does GDR.L fit in your portfolio?
Add your other holdings to see your portfolio's Sharpe Ratio and find out.
